CXCR4 and WHIM syndrome: As CXCR4 GOF mutations play a central role in the pathogenesis of WHIM syndrome, correction of aberrant CXCR4 signaling using CXCR4 antagonists including plerixafor and mavorixafor has been explored as a potential therapeutic approach for the treatment of WHIM syndrome (19–24).